Related Experiment Videos
Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols
C B Gable1, J C Tierce, D Simison
1State and Federal Associates, Alexandria, VA 22314, USA.
Insights
This study outlines HIV/AIDS treatment costs based on CD4+ counts, projecting lifetime expenses for effective resource management. Annual costs range from $1,934 to $25,239, with an estimated lifetime cost of $94,726.
Area of Science:
- Public Health
- Health Economics
- Infectious Diseases
Background:
- Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) management requires understanding treatment costs.
- CD4+ T-lymphocyte counts serve as a critical indicator for disease progression and treatment intensity in HIV/AIDS patients.
Purpose of the Study:
- To define HIV/AIDS treatment protocols stratified by CD4+ T-lymphocyte counts.
- To project the annual and lifetime costs associated with HIV/AIDS patient care.
- To provide a framework for better cost definition and resource allocation in HIV/AIDS management.
Main Methods:
- Treatment protocols were developed from literature review and an expert HIV/AIDS Physician Panel.
- Resource utilization for antiretroviral therapy, opportunistic disease prophylaxis, and treatment was defined.
- Cost data were sourced from literature, insurance databases, Medicare fee schedules, surveys, and the Physician Panel.
Main Results:
- Annual costs for HIV/AIDS patients varied significantly by CD4+ count: $1,934 (≥500), $6,015 (200-499), $9,031 (50-199), and $25,239 (<50).
- Specific opportunistic diseases incurred substantial annual costs, e.g., cytomegalovirus retinitis ($100,337) and severe Pneumocystis carinii pneumonia ($32,609).
- Projected lifetime costs for HIV/AIDS were estimated at $94,726, with average annual costs of $7,645.
Conclusions:
- The study provides a cost framework for HIV/AIDS care based on CD4+ T-lymphocyte counts.
- Lower lifetime cost estimates compared to previous studies may reflect focused resource allocation and improved treatment efficiencies.
- Observed cost reductions are attributed to shorter hospital stays, fewer hospitalizations, and increased outpatient care.
Abstract:
We report treatment protocols for HIV+/AIDS patients by CD4+ counts (T-lymphocyte cells/mm3: > or = 500, 499-200, 199-50, and < 50) as a tool to provide better definition and to project annual costs (total charges for services) and lifetimes costs for HIV+/AIDS. The treatment protocols, derived from the literature and an HIV+/AIDS Physician Panel, defined the resource use associated with antiretroviral therapy and opportunistic disease prophylaxis and treatment. Resource use costs were derived from the published literature, insurance database, Medicare fee schedules, surveys, and the Physician Panel. At CD4+ counts, the rates of opportunistic diseases were derived from the Physician Panel experience; the mean occupancy times were derived from the literature. The sensitivity analysis indicated stability of the lifetime costs to variation in mean occupancy times, rates of opportunistic diseases, rates of adverse events (AE), and costs. The total annual costs (1995 dollars) of HIV+/AIDS patients ranged from $1,934 (> or = 500), $6,015 (200-499), and $9,031 (50-199), to $25,239 ( < 50). The annual costs of opportunistic diseases are esophageal candidiasis (EC) ($2,194), tuberculosis (TB) ($2,924), cryptococcal meningitis (CM) ($17,264), toxoplasmosis ($17,631), Mycobacterium avium complex (MAC) (+20,153), Non-Hodgkin's lymphoma (NHL) ($22,329), wasting syndrome ($26,676), central nervous system (CNS) lymphoma ($27,333), Pneumocystis carinii pneumonia (PCP) [mild ($3,545), moderate ($4,889), and severe ($32,609)], Kaposi' sarcoma (KS) [mild/moderate ($5,902), and severe ($10,744)], and cytomegalovirus (CMV) retinitis ($100,337). The projected lifetime costs of HIV+/AIDS are $94,726 (annual costs $7,645). Our lower lifetime costs as compared with recent estimates may be due to including resources only for HIV+/AIDS-related treatment and not for non-HIV+/AIDS conditions, as well as reduced resource use resulting from more efficient diagnostic and therapeutic techniques and earlier prophylaxis provided by experienced HIV+/AIDS physicians. Nonetheless, our estimates are consistent with decreasing costs of HIV+/AIDS due to a reduction in the average length of stay and frequency of hospitalizations as well as to replacement of inpatient care by outpatient services.